By volume, Augmentin was way higher than Mounjaro with 5,784 units sold during October, compared to just 85 units sale of ...

Eli Lilly's Mounjaro became India's highest-selling drug in October with ₹100 crore sales. The anti-obesity treatment now ...

Eli Lilly's weight-loss therapy Mounjaro became India's top-selling drug by value in October, data showed on Friday, ...

Eli Lilly's blockbuster obesity ​drug Mounjaro became India's ‌top-selling drug by value for the ‌month of October with sales ...

Eli Lilly recorded ₹1 billion in Mounjaro sales in October, compared to Augmentin’s ₹800 million ・Since its March 2025 launch ...

Eli Lilly's Mounjaro tops India's drug sales in October, surpassing GSK's Augmentin with ₹100 crore in revenue.

The anti-obesity drug registered sales of ₹100 crore in October, unseating the previous best-selling antibiotic Augmentin, ...

Early results of Eli Lilly’s next generation of weight loss drugs appear to show promise, possibly leading to even faster ...

Mounjaro, the breakthrough obesity and diabetes drug from Eli Lilly and Company, has become India’s highest-selling pharmaceutical brand in October, according to fresh data from market intelligence ...

Eli Lilly and Company (NYSE: LLY) today announced the appointment of two new Executive Committee members and the expansion of ...

Eli Lilly's next generation of weight loss drugs appear to show promise, possibly leading to even faster weight loss and ...

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...